Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model

JCI Insight. 2023 Apr 10;8(7):e167306. doi: 10.1172/jci.insight.167306.

Abstract

Currently authorized COVID-19 vaccines induce humoral and cellular responses to epitopes in the SARS-CoV-2 spike protein, though the relative roles of antibodies and T cells in protection are not well understood. To understand the role of vaccine-elicited T cell responses in protection, we established a T cell-only vaccine using a DC-targeted lentiviral vector expressing single CD8+ T cell epitopes of the viral nucleocapsid, spike, and ORF1. Immunization of angiotensin-converting enzyme 2-transgenic mice with ex vivo lentiviral vector-transduced DCs or by direct injection of the vector induced the proliferation of functional antigen-specific CD8+ T cells, resulting in a 3-log decrease in virus load upon live virus challenge that was effective against the ancestral virus and Omicron variants. The Pfizer/BNT162b2 vaccine was also protective in mice, but the antibodies elicited did not cross-react on the Omicron variants, suggesting that the protection was mediated by T cells. The studies suggest that the T cell response plays an important role in vaccine protection. The findings suggest that the incorporation of additional T cell epitopes into current vaccines would increase their effectiveness and broaden protection.

Keywords: COVID-19; Dendritic cells; Immunology; T cells.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Epitopes, T-Lymphocyte
  • Humans
  • Mice
  • Mice, Transgenic
  • Models, Animal
  • SARS-CoV-2
  • Vaccines*

Substances

  • spike protein, SARS-CoV-2
  • COVID-19 Vaccines
  • Epitopes, T-Lymphocyte
  • BNT162 Vaccine
  • Vaccines
  • Antibodies

Supplementary concepts

  • SARS-CoV-2 variants